{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+the+Ovaries",
    "query": {
      "condition": "Adenocarcinoma of the Ovaries"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 27,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+the+Ovaries&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T22:32:34.698Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00019916",
      "title": "Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "p53 peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "in vitro-treated peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "2000-06",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2013-06-20",
      "last_synced_at": "2026-05-21T22:32:34.698Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019916"
    },
    {
      "nct_id": "NCT06051695",
      "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Colorectal Cancer",
        "NSCLC",
        "Non Small Cell Lung Cancer",
        "NSCLC, Recurrent",
        "Non-Small Cell Squamous Lung Cancer",
        "Pancreas Cancer",
        "Pancreatic Neoplasm",
        "Colorectal Adenocarcinoma",
        "CRC",
        "Colon Cancer",
        "Rectal Cancer",
        "Cancer",
        "Ovarian Cancer",
        "Ovarian Neoplasms",
        "Mesothelioma",
        "Mesothelioma, Malignant",
        "Ovary Cancer",
        "Lung Cancer",
        "MESOM"
      ],
      "interventions": [
        {
          "name": "A2B694",
          "type": "BIOLOGICAL"
        },
        {
          "name": "A2B543",
          "type": "BIOLOGICAL"
        },
        {
          "name": "xT CDx with HLA-LOH Assay",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "A2 Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 474,
      "start_date": "2024-04-03",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-05-21T22:32:34.698Z",
      "location_count": 12,
      "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06051695"
    },
    {
      "nct_id": "NCT00585845",
      "title": "Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Epithelial Mesothelioma",
        "Adenocarcinoma of the Pancreas",
        "Carcinoma, Non-Small-Cell Lung",
        "Adenocarcinoma of the Ovaries"
      ],
      "interventions": [
        {
          "name": "CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Anza Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2007-12",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2009-02-20",
      "last_synced_at": "2026-05-21T22:32:34.698Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00585845"
    },
    {
      "nct_id": "NCT03281681",
      "title": "A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "VAL-083, Dianhydrogalactitol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DelMar Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-03",
      "completion_date": "2022-09",
      "has_results": false,
      "last_update_posted_date": "2019-10-18",
      "last_synced_at": "2026-05-21T22:32:34.698Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Detroit, Michigan • Nashville, Tennessee",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03281681"
    },
    {
      "nct_id": "NCT02315430",
      "title": "Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Ovarian Clear Cell Adenocarcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 13,
      "start_date": "2015-04-01",
      "completion_date": "2019-02-09",
      "has_results": true,
      "last_update_posted_date": "2020-03-10",
      "last_synced_at": "2026-05-21T22:32:34.698Z",
      "location_count": 410,
      "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 275 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02315430"
    },
    {
      "nct_id": "NCT05292859",
      "title": "Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gynecologic Cancer",
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Non-small Cell Lung Cancer",
        "Cholangiocarcinoma",
        "Ovarian Cancer",
        "Ovary Neoplasm",
        "Squamous Cell Lung Cancer",
        "Adenocarcinoma of Lung",
        "Adenosquamous Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Neoantigen specific TCR-T cell drug product",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alaunos Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2023-03-01",
      "completion_date": "2025-05-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-30",
      "last_synced_at": "2026-05-21T22:32:34.698Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05292859"
    },
    {
      "nct_id": "NCT05538624",
      "title": "A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasm, Ovarian",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cavity Cancer",
        "Adenocarcinoma Ovary",
        "Serous Adenocarcinoma of Ovary",
        "Serous Adenocarcinoma of Primary Peritoneum",
        "Primary Peritoneal Carcinoma",
        "High Grade Serous Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "AVB-001 (Dose Escalation Phase)",
          "type": "DRUG"
        },
        {
          "name": "AVB-001 (Dose Expansion Phase)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avenge Bio, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2022-12-09",
      "completion_date": "2024-04-10",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-05-21T22:32:34.698Z",
      "location_count": 5,
      "location_summary": "Bethesda, Maryland • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05538624"
    },
    {
      "nct_id": "NCT05446298",
      "title": "ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "High Grade Serous Adenocarcinoma of Ovary",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "ONC-392",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoC4, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 58,
      "start_date": "2022-12-22",
      "completion_date": "2026-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-21T22:32:34.698Z",
      "location_count": 21,
      "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Danbury, Connecticut + 18 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Hinsdale",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05446298"
    },
    {
      "nct_id": "NCT00354601",
      "title": "Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 2,
      "start_date": "2006-01",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2017-08-30",
      "last_synced_at": "2026-05-21T22:32:34.698Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00354601"
    },
    {
      "nct_id": "NCT06466187",
      "title": "A Study of SGN-MesoC2 in Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Ovarian Neoplasms",
        "Pancreatic Adenocarcinoma",
        "Colorectal Neoplasms",
        "Mesothelioma",
        "Other Solid Tumors",
        "Endometrial"
      ],
      "interventions": [
        {
          "name": "PF-08052666",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2024-08-02",
      "completion_date": "2029-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-05-21T22:32:34.698Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Fairway, Kansas • Kansas City, Kansas + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06466187"
    }
  ]
}